Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Incy save search
Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.49%
H: 0.84%
C: -0.07%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.09%
H: 1.42%
C: 1.1%
ibi310 first cancer colon therapy study
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
Innovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
Published: 2023-12-01 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.15%
H: 0.35%
C: -0.74%
ibi351 lung congress update cancer asia
Pancreatic Cancer Battle Boosted by $200M VC Firm
Published: 2023-09-19 (Crawled : 17:00) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: -1.47%
H: 4.98%
C: 3.98%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.13%
H: 2.0%
C: 1.83%
MACK 4 | $14.72 -0.07% -0.07% 110K
|
Health Technology
|
| O: -0.41%
H: 0.9%
C: 0.74%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.03%
H: 2.18%
C: 1.8%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -0.01%
H: 1.99%
C: 1.28%
cancer pancreatic
Innovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
Published: 2023-08-08 (Crawled : 03:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.09%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
ibi363 antibody cancer preclinical results
Bladder Cancer Market Likely to Exhibit Substantial Growth, Assesses DelveInsight | Leading Companies - CicloMed, Bristol-Myers Squibb, CG Oncology, Merck, Eli Lilly and Company, UroGen, Ferring
Published: 2023-08-07 (Crawled : 21:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.19%
H: 0.0%
C: -2.72%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 11.43%
H: 6.32%
C: 3.08%
URGN | $14.24 -2.0% -2.04% 97K
|
Health Technology
|
| O: -1.3%
H: 6.76%
C: 5.57%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 2.58%
H: 0.41%
C: -1.13%
FUSN | $21.4 -0.09% -0.09% 270K
|
Health Technology
|
| O: 10.6%
H: 0.0%
C: -9.58%
companies bladder cancer market
Esophageal Cancer Market to Proliferate at a CAGR of 5.9% During the Study Period (2019-2032), Estimates DelveInsight
Published: 2023-07-06 (Crawled : 21:00) - prnewswire.com
ATNXQ | $0.0152 -85.53% 3.6K
|
Manufacturing
|
| O: 54.31%
H: 0.0%
C: -29.37%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.19%
H: 0.28%
C: -2.22%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.17%
H: 0.72%
C: -0.97%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
LPTX | $3.285 2.66% 2.59% 190K
|
Health Technology
|
| O: -0.79%
H: 6.03%
C: -0.63%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.14%
H: 0.16%
C: -1.12%
ICLR | News | $308.79 0.76% 0.76% 960K
|
Health Technology
|
| O: 0.05%
H: 0.64%
C: -0.47%
CRIS | $14.705 -2.03% -2.07% 4.7K
|
Health Technology
|
| O: 1.29%
H: 5.24%
C: -5.26%
BCEL P | $0.08 0.0% 160K
|
Health Technology
|
| O: -1.1%
H: 7.53%
C: 5.06%
cancer study market
Metastatic Pancreatic Cancer Market to Proliferate Immensly, Predicts DelveInsight | Key Companies to Look Out for - FibroGen, AstraZeneca, Jiangsu HengRui, ImmunityBio, SynerGene, Mirati, Incyte, Astellas, AbbVie, Cue Biopharma, PureTech
Published: 2023-06-15 (Crawled : 15:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -0.92%
H: 0.0%
C: -0.37%
BMEA | $10.76 -2.0% -2.04% 750K
|
Professional, Scientific, and T...
|
| O: -0.15%
H: 0.0%
C: -5.2%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.06%
H: 1.91%
C: 1.32%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.11%
H: 2.08%
C: 1.97%
companies cue cancer pancreatic market
Innovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
Published: 2023-06-06 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.8%
H: 0.23%
C: -1.06%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.94%
H: 0.27%
C: 0.02%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.45%
H: 0.14%
C: -1.5%
ibi351 asco cancer meeting
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
Published: 2023-05-08 (Crawled : 15:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.11%
H: 0.72%
C: 0.3%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: 6.91%
H: 1.49%
C: -2.49%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 4.23%
H: 0.0%
C: -4.4%
ADAP | $1.085 -4.83% -5.07% 780K
|
Health Technology
|
| O: 1.43%
H: 2.11%
C: -1.41%
companies report cancer pancreatic global
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
Published: 2023-05-08 (Crawled : 00:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.38%
H: 2.06%
C: 1.53%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
rient-31 lung lancet respiratory cancer cell plus results study
Innovent Announces NMPA's Breakthrough Therapy Designation for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Previous Treated Advanced Non-small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.59%
H: 0.15%
C: -0.56%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.63%
H: 2.86%
C: 2.01%
ibi351 designation lung therapy cancer
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
Published: 2023-01-02 (Crawled : 16:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
| Email alert
Add to watchlist
RCUS 4 | $15.43 -0.45% 0.0% 520K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
| Email alert
Add to watchlist
QLGN | $0.296 -6.03% -6.42% 24K
|
Health Technology
| Email alert
Add to watchlist
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
| Email alert
Add to watchlist
AGEN A | $7.42 14.86% 12.94% 1.3M
|
Health Technology
| Email alert
Add to watchlist
MRUS | $41.96 2.79% 2.72% 740K
|
Health Technology
| Email alert
Add to watchlist
GRTX | $0.1821 -6.13% -6.53% 810K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
| Email alert
Add to watchlist
treatment cancer pancreatic
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
immunotherapy meeting cancer
Esophageal Cancer Clinical Trial Pipeline Insights Featuring 80+ Companies | DelveInsight
Published: 2022-10-11 (Crawled : 16:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.2%
H: 2.82%
C: 2.38%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
LPTX | $3.285 2.66% 2.59% 190K
|
Health Technology
|
| O: -1.15%
H: 5.35%
C: -0.7%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.27%
H: 0.59%
C: -0.75%
CRIS | $14.705 -2.03% -2.07% 4.7K
|
Health Technology
|
| O: -2.18%
H: 3.89%
C: -1.35%
BCEL P | $0.08 0.0% 160K
|
Health Technology
|
| O: -1.26%
H: 5.1%
C: -1.91%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 1.95%
H: 0.0%
C: -11.04%
companies trial cancer
New treatment for rare cancer cholangiocarcinoma approved in Australia
Published: 2022-09-15 (Crawled : 14:20) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.29%
H: 1.73%
C: 1.11%
treatment rare australia approved cancer
Bladder Cancer Clinical Trial Pipeline Insights Featuring 100+ Companies | DelveInsight
Published: 2022-08-23 (Crawled : 16:00) - prnewswire.com
IBRX | $4.815 -12.3% -14.02% 7.9M
|
Manufacturing
|
| O: 0.27%
H: 6.27%
C: 4.0%
URGN | $14.24 -2.0% -2.04% 97K
|
Health Technology
|
| O: 0.64%
H: 0.32%
C: -0.63%
TARA | $2.81 -6.33% -6.76% 420K
|
Health Technology
|
| O: -0.38%
H: 3.83%
C: 1.73%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.49%
H: 0.36%
C: -0.33%
companies trial bladder cancer
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
Published: 2022-07-08 (Crawled : 21:00) - globenewswire.com
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
| Email alert
Add to watchlist
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
| Email alert
Add to watchlist
mga271 plus cancer study
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
Published: 2022-04-22 (Crawled : 16:00) - biospace.com/
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.4%
H: 1.01%
C: 0.04%
tabrecta treatment chmp positive cancer
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
Published: 2022-04-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.36%
H: 0.24%
C: -0.62%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.52%
H: 1.58%
C: 0.22%
ibi310 treatment cancer designation antibody
Gainers vs Losers
| 65% | 35% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 210M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.